Super Bowl, Hims and Food and Drug Administration

Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.
Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business
Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.
Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs
The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.
What is compounded semaglutide and is it safe? The weight loss drugs Hims & Hers is selling, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
Hims & Hers Super Bowl commercial: Ad draws ire from drug industry
Hims & Hers makes its Super Bowl commercial debut in 2025 with a spot for the telehealth company's weight loss medications. Set to the "This Is America" by Childish Gambino (Donald Glover), the commercial calls out weight loss prescriptions and the weight-loss industry that "feeds on our failure."
Hims & Hers Super Bowl Spot Draws Drug-Industry Backlash
Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto against weight-loss treatments priced “for profits, not patients,” after critici
3 Weight-Loss Drug Stocks to Watch
Weight-loss drugs have been popular over the past couple of years, and Hims & Hers Health Inc (NYSE:HIMS), Novo Nordisk A/S ( NYSE:NVO), and Viking Therapeutics Inc (NASDAQ:VKTX) are among the most recognized names in the industry. Below, we check in with these pharma giants to see how they are faring.
Hims & Hers stock sees another spike in trading days after Super Bowl ad
Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.
Weight Loss Drug Super Bowl Ad Raises Questions About Compounded Vs. Branded Meds
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.
Doctor weighs in on controversial weight loss drug commercial
The ad from the telehealth company Hims & Hers promoted the company’s compounded weight loss drugs. The ad portrayed the obesity epidemic as a rigged game because of the greedy health care system. Dr.
Hims & Hers Super Bowl Ad Controversy - Here's The Latest
Hims & Hers faced backlash over its Super Bowl ad touting its compound weight loss drug while slamming pharmaceutical giants for profiting from America's obesity crisis. The company attracted flak from US Senators,
Hims & Hers markets itself in a very 2025 way: by picking a fight
Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.
USA Today7d
Drug industry groups target Hims & Hers Super Bowl ad touting weight loss drug
Drug industry allies are calling out a Super Bowl ad touting its weight loss medications from telehealth company Hims & Hers, claiming the spot doesn't adequately disclose safety risks of ...
Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading' patients
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...